Skip to main content
Clinical Trials/NCT06101459
NCT06101459
Not yet recruiting
Not Applicable

A Study About Association Between Microbiome, Metabolome and Clinical Characteristics in COPD Patients

Asan Medical Center0 sites300 target enrollmentDecember 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Obstructive Pulmonary Disease
Sponsor
Asan Medical Center
Enrollment
300
Primary Endpoint
Propionic acid level
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this observational registry study is to compare characteristics of gut and sputum microbiome and metabolome among COPD patients with significant smoking history, COPD patients without significant smoking history and healthy smoker. Additionally, the investigators investigate the difference of blood metabolites and peripheral blood mononuclear cells level among groups.

The main questions it aims to answer are:

  • Are there significant difference in fecal or sputum microbiome and metabolome between COPD patients and healthy smoker?
  • Are there any distinct characteristics in microbiome and metabolome in COPD with COPD patients with significant smoking history, COPD patients without significant smoking history compared with healthy smoker?
  • Are there any difference in blood metabolites and peripheral blood mononuclear cells levels among patients with significant smoking history, COPD patients without significant smoking history and healthy smoker
  • Might distinct characteristics of microbiome and metabolites in COPD patients be related to worse clinical outcomes in COPD patients?
Registry
clinicaltrials.gov
Start Date
December 1, 2023
End Date
December 31, 2028
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sei Won Lee

Professor

Asan Medical Center

Eligibility Criteria

Inclusion Criteria

  • COPD Patients, defined by FEV1/FVC \<0.7, who
  • agree with informed consent
  • have no history of acute exacerbation within 3 months
  • Healthy smoker without airflow limitation, defined by FEV1/FVC ≥0.7, who
  • have smoking history with at least 30 pack-year
  • agree with informed consent
  • do not use medication for chronic respiratory disease

Exclusion Criteria

  • Withdrawal of informed consent
  • History of acute exacerbation or antibiotics use within 3 months
  • Difficulty to collect adequate stool, sputum and blood samples

Outcomes

Primary Outcomes

Propionic acid level

Time Frame: At enrollment

the investigators will compare the Propionic acid level among groups

Shannon diversity index

Time Frame: At enrollment

the investigators will compare alpha diversity and community similarity among groups by using the Shannon diversity index.

Simpson index

Time Frame: At enrollment

the investigators will compare alpha diversity and community similarity among groups by using the Simpson index.

Principal component analysis

Time Frame: At enrollment

the investigators will compare beta diversity and community similarity among groups by using the principal component analysis.

Peripheral blood mononuclear cells level

Time Frame: At enrollment

the investigators will compare the Peripheral blood mononuclear cells level among groups

Valeric acid level

Time Frame: At enrollment

the investigators will compare the valeric acid level among groups

Microbiome composition by metagenomic analysis

Time Frame: At enrollment

The composition of microbiome will be presented as bar graph.

Isobutyric acid level

Time Frame: At enrollment

the investigators will compare the Isobutyric acid level among groups

Isovaleric acid level

Time Frame: At enrollment

the investigators will compare the Isovaleric acid level among groups

secondary bile acid level

Time Frame: At enrollment

the investigators will compare the secondary bile acid level among groups

Acetic acid level

Time Frame: At enrollment

the investigators will compare the acetic acid level among groups

Butyric acid level

Time Frame: At enrollment

the investigators will compare the butyric acid level among groups

dimethylglycine level

Time Frame: At enrollment

the investigators will compare the dimethylglycine level among groups

Secondary Outcomes

  • Difference of metabolome according to Exacerbation(within 1 year after enrollment)
  • Difference of microbiome according to Exacerbation(within 1 year after enrollment)
  • Difference of microbiome according to death(within 1 year after enrollment)
  • Difference of metabolome according to death(within 1 year after enrollment)

Similar Trials